Avidity engineering of human heavy-chain-only antibodies mitigates neutralization resistance of SARS-CoV-2 variants.
Du W, Janssens R, Mykytyn AZ, Li W, Drabek D, van Haperen R, Chatziandreou M, Rissmann M, van der Lee J, van Dortmondt M, Martin IS, van Kuppeveld FJM, Hurdiss DL, Haagmans BL, Grosveld F, Bosch BJ.
Du W, et al. Among authors: martin is.
Front Immunol. 2023 Feb 21;14:1111385. doi: 10.3389/fimmu.2023.1111385. eCollection 2023.
Front Immunol. 2023.
PMID: 36895554
Free PMC article.